(2E)-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenoic acid methyl ester | 404951-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (2E)-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenoic acid methyl ester
• 英文别名: (E)-3-(4-{[2-(1H-indol-3-yl)ethylamino]methyl}phenyl)acrylic acid methyl ester；methyl (E)-3-(4-(((2-(1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylate；(E)-methyl 3-(4-((2-(1H-indol-3-yl)ethylamino)methyl)phenyl)acrylate；3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester；(E)-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylic acid methyl ester；methyl 3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylate；methyl (E)-3-[4-[[2-(1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enoate
• CAS: 404951-55-9
• 化学式: C₂₁H₂₂N₂O₂
• 分子量: 334.418
• InChiKey: JSFKISZGHQAGKO-ZHACJKMWSA-N

物化性质

• 沸点：
  541.4±40.0 °C(Predicted)
• 密度：
  1.187±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2E)-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenoic acid methyl ester 在 sodium hydroxide 、 羟胺 作用下， 以 甲醇 为溶剂， 以96%的产率得到N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide
  参考文献：
  名称：

  N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity:  Discovery of (2E)-N-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824)

  摘要：

  A series of N-hydroxy-3-phenyl-2-propenamides were prepared as novel inhibitors of human histone deacetylase (HDAC). These compounds were potent enzyme inhibitors, having IC(50)s < 400 nM in a partially purified enzyme assay. However, potency in cell growth inhibition assays ranged over 2 orders of magnitude in two human carcinoma cell lines. Selected compounds having cellular IC50 < 750 nM were tested for maximum tolerated dose (MTD) and for efficacy in the HCT116 human colon tumor xenograft assay. Four compounds having an MTD 100 mg/kg were selected for dose-response studies in the HCT116 xenograft model. One compound, 9 (NVP-LAQ824), had significant dose-related activity in the HCT116 colon and A549 lung tumor models, high MTD, and low gross toxicity. On the basis, in part, of these properties, 9 has entered human clinical trials in 2002.

  DOI：

  10.1021/jm030235w
• 作为产物：
  描述：

  色胺 、 (E)-3-(4-醛基苯基)丙烯酸甲酯 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以65%的产率得到(2E)-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenoic acid methyl ester
  参考文献：
  名称：

  具有潜力的体外和体内抗肿瘤活性的有效烟酰胺磷酸核糖基转移酶抑制剂的基于结构的设计。

  摘要：

  烟酰胺磷酸核糖基转移酶（NAMPT）的抑制作用有可能直接限制癌细胞中NAD的产生，是治疗癌症的有效策略。使用基于结构的策略，我们设计了一类新型的NAMPT强效小分子抑制剂。几种设计的化合物在体外显示出有希望的抗增殖活性。（E）-N-（5-（（4-（（（（2-（1 H-吲哚-3-基）乙基）（异丙基氨基）甲基）苯基）氨基）戊基）-3-（吡啶基-3带有吲哚部分的30-基）丙烯酰胺的IC 50为25.3 nM，可与NAMPT蛋白结合，并且在纳摩尔范围内表现出对几种癌细胞系的有希望的抑制活性（MCF-7 GI 50= 0.13 nM；MDA-MB-231 GI 50 = 0.15 nM）。三阴性乳腺癌是最恶性的乳腺癌亚型，目前尚无有效的靶向治疗方法。在原位MDA-MB-231三阴性乳腺癌异种移植肿瘤模型中，实现了化合物30的显着抗肿瘤功效（TGI为73.8％）。本文报道了有希望的抑制NAMPT的先导分子，可作为进一步研究的基础。

  DOI：

  10.1021/acs.jmedchem.6b00324

文献信息

• [EN] ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES<br/>[FR] HYDROXAMATES CONNECTES A L'ACYLUREE ET A LA SULFONYLUREE
  申请人：S BIO PTE LTD

  公开号：WO2005040101A1

  公开（公告）日：2005-05-06

  The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities.

  本发明涉及羟肟酸酯化合物，这些化合物是组蛋白去乙酰化酶的抑制剂。更具体地，本发明涉及含有酰脲/磺酰脲的化合物及其制备方法。这些化合物可能作为治疗增殖性疾病以及涉及、与组蛋白去乙酰化酶活性有关的其他疾病的药物而有用。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE
  申请人：METHYLGENE INC

  公开号：WO2005092899A1

  公开（公告）日：2005-10-06

  The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

  这项发明涉及一系列对抑制组蛋白去乙酰化酶（HDAC）酶活性有用的化合物。该发明还提供了一种利用这些化合物抑制细胞中组蛋白去乙酰化酶的方法，以及一种利用这些HDAC抑制剂治疗细胞增殖性疾病和病况的方法。此外，该发明提供了包含这些HDAC抑制化合物和药用可接受载体的药物组合物。
• [EN] SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF<br/>[FR] AGENTS DE DÉGRADATION SÉLECTIFS D'HISTONE DÉSACÉTYLASES 6/8 (HDAC6/8) ET LEURS PROCÉDÉS D'UTILISATION
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2021092153A1

  公开（公告）日：2021-05-14

  The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylases 6 and 8 (HDAC6/8) activity.

  本发明涉及用于治疗由异常组蛋白去乙酰化酶6和8（HDAC6/8）活性介导的疾病或症状的双功能化合物、组合物和方法。
• Hydroxamate-Based Inhibitors of Deacetylases
  申请人：CHO Young Shin

  公开号：US20110053925A1

  公开（公告）日：2011-03-03

  The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , ring A, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

  本教导涉及到Formula I的化合物，以及其药用盐、水合物、酯和前药，其中R1、R2、R3、环A和如此定义。本教导还提供了制备Formula I化合物的方法，以及利用Formula I化合物治疗、抑制或预防完全或部分由去乙酰酶介导的病理状况或紊乱的方法。
• [EN] HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES<br/>[FR] COMPOSÉS À BASE D'HYDROXAMATE EN TANT QU'INHIBITEURS DES DÉSACÉTYLASES
  申请人：NOVARTIS AG

  公开号：WO2012025155A1

  公开（公告）日：2012-03-01

  The present teachings relate to compounds of Formula I and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, ring A, and ( formula II) are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

  本教导涉及到Formula I的化合物及其药用盐、水合物、酯和前药，其中R1、R2、R3、环A和（Formula II）如本文所定义。本教导还提供了制备Formula I化合物的方法，以及利用Formula I化合物治疗、抑制或预防完全或部分由去乙酰化酶介导的病理状况或疾病的方法。